louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01588886: Proton Pump Inhibitor Use is Associated With High Risk of Pneumonia in Chronic Kidney Disease Patients
Official title: Institute of Emergency and Critical Care Medicine , School of Yang-Ming University
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Kidney Disease
Pneumonia
Keywords: Proton pump inhibitors
Pneumonia
Retrospective cohort study
Lead sponsor: Far Eastern Memorial Hospital
Sponsor class: OTHER
First posted: 2012-05-01
Enrollment: 9000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Investiators use the longitudinal health insurance database 2008 (LHID 2008) released by the Taiwan National Health Research Institutes (NHRI) in 2009. Taiwan implemented its National Health Insurance (NHI) program in 1995 to provide affordable health care for all the island's residents.

Brief summary: Chronic kidney disease is a severe medical problem in Taiwan public health issue, which the highest incidence and prevalence rate in the world.Proton pump inhibitors may increase the risk of pneumonia appearance, which were caused by profound irreversible gastric acid suppression. The study purpose was to characterize difference of developing pneumonia in chronic kidney disease of prior use proton pump inhibitors.

Detailed description: The study used data from Taiwan Health Insurance Research Database; the investigators conducted a population-based cohort study in Taiwan. Case consisted of all patients who had a first diagnosis of chronic kidney disease for the period between 1997 and 2008. The investigators utilized the use of Proton pump inhibitor from chronic kidney disease patients.

Eligibility criteria: Inclusion Criteria:

* Chronic kidney disease

Exclusion Criteria:

* excluded those patients who had ever been diagnosed with CKD before 1997

Primary outcomes:
measure: Chronic kidney disease ICD-9
timeFrame: 2012-Dec
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: west-garden Hospital
name: Chen Chih-Hung, MD
role: STUDY_DIRECTOR
References:
citation: Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011 Apr;56(4):931-50. doi: 10.1007/s10620-010-1560-3. Epub 2011 Mar 2.
citation: Wu H, Jing Q, Wang J, Guo X. Pantoprazole for the prevention of gastrointestinal bleeding in high-risk patients with acute coronary syndromes. J Crit Care. 2011 Aug;26(4):434.e1-6. doi: 10.1016/j.jcrc.2010.12.007. Epub 2011 Jan 26.
citation: Madanick RD. Proton pump inhibitor side effects and drug interactions: much ado about nothing? Cleve Clin J Med. 2011 Jan;78(1):39-49. doi: 10.3949/ccjm.77a.10087.
Clinical trial NCT05059886: The Injury and Its Consequences in the Sports Lower Limb Amputee
Official title: The Injury and Its Consequences in the Sports Lower Limb Amputee
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Leg Lower Amputation
Traumatic Amputation
Keywords: sport
lower limb amputation
Lead sponsor: Centre Hospitalier Universitaire de Nīmes
Sponsor class: OTHER
First posted: 2021-09-28
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Lower limb amputee or agenic lower limb with regular physical activity (at least 1x/week)

Brief summary: This study was motivated by the lack of data in the literature on the injury of the major lower limb amputee playing sports and its socio-professional impact.

It aims to study sports-related injuries in lower limb amputees. Its objective is to determine the prevalence, but also to describe the injuries (type, location, duration, type of management) and their repercussions in terms of after-effects, and repercussions on sports, professional and personal practice. It also aims to begin a correlation between injury and sports load, type of sport (discipline, practice modality), technical aids used


Eligibility criteria: Inclusion Criteria:

* Lower limb amputee or lower limb agenes
* Amputee before 55 years old
* Amputee for more than 2 years
* Willing to participate in the study
* Practicing a regular physical activity (at least 1x/week)
* Patient affiliated or beneficiary of a health insurance plan.
* Patient aged 18-65 years

Exclusion Criteria:

* None

Primary outcomes:
measure: prevalence of injuries
timeFrame: in the 5 years preceding the completion of the questionnaire
Secondary outcomes:
Other outcomes:
Locations:
city: Nîmes
country: France
facility: CHU de Nîmes
Study officials:
affiliation: Centre Hospitalier Universitaire de Nīmes
name: Anissa MEGZARI
role: STUDY_DIRECTOR
References:
Clinical trial NCT01906086: Effects of Legume Consumption on Adiponectin and Inflammatory Markers Among Adults
Official title: Effects of Legume Consumption on Adiponectin and Inflammatory Markers Among First Degree Relatives of Diabetic Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus, Type 2
Lead sponsor: Isfahan University of Medical Sciences
Sponsor class: OTHER
First posted: 2013-07-23
Enrollment: 26
Sex: ALL
Minimum age (years): 30
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The aim of this randomized cross-over study was to determine the effects of legume consumption on adiponectin and inflammatory factors among first degree relatives of diabetic patients


Eligibility criteria: Inclusion Criteria:

* age more than 30 years
* no history of chronic diseases
* no use of blood glucose lowering drugs

Exclusion Criteria:

* do not use recommended amounts of legumes
* incidence of chronic diseases during the study
* to start use of blood glucose lowering drugs

Primary outcomes:
measure: high sensitive C reactive protein (mg/l)
timeFrame: 14 weeks
Secondary outcomes:
measure: Interleukin-6 (pg/ml)
timeFrame: 14 weeks
measure: Tumor necrosis factor-α (pg/ml)
timeFrame: 14 weeks
measure: Adiponectin (ng/ml)
timeFrame: 14 weeks
Other outcomes:
Locations:
city: Isfahan
country: Iran, Islamic Republic of
facility: Isfahan University of Medical Sciences
Study officials:
References:
Clinical trial NCT06189586: Comparison of Aerosol Inhalation and Intravenous Glucocorticoid in the Treatment of Severe AECOPD
Official title: Comparison of Aerosol Inhalation and Intravenous Glucocorticoid in the Treatment of Severe AECOPD-------Multicenter, Prospective, Randomized, Controlled Clinical Study
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Keywords: severe AECOPD
aerosol inhalation and intravenous glucocorticoid
Lead sponsor: Jilin University
Sponsor class: OTHER
Collaborators: name: Jilin University
First posted: 2024-01-03
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Description for medicine or protocol of treatment in detail:

Dosing regimen:

1. Intravenous hormone group: 40mg sodium methylprednisolone succinate for injection(dissolved in 0.9% saline or5% glucose injection 50ml), intravenous infusion for 30 minutes, once a day for 5 consecutive days.
2. Nebulized inhalation group: 2 mg budesonide suspension for inhalation, nebulized inhalation for minutes,administered 4 times a day for 5 consecutive days.
Primary purpose: TREATMENT

Brief summary: Comparison of aerosol inhalation and intravenous glucocorticoid in the treatment of severe AECOPD-------Multicenter, prospective, randomized, controlled clinical study

Detailed description: This study aims to compare the efficacy and comprehensive benefits of aerosol inhalation and intravenous injection of glucocorticoids in severe AECOPD patients.

Eligibility criteria: Inclusion Criteria:

(1) Patients with AECOPD requiring hospitalization or emergency treatment (COPD acute attacks combined with respiratory failure were eligible). (2) 18 years of age ≤80 years of age (3) Patients and their families are willing to participate in clinical research and sign informed consent.

Exclusion Criteria:

1. Combined with tuberculosis.
2. Combined bronchiectasis.
3. complicated with definite infectious diseases.
4. PCT≥0.5ng/ml or CRP≥30mg/L.
5. Serious injury combined with other organ functions
6. Contraindications to other glucocorticoid use.
7. Concomitant bronchial asthma or positive bronchodilation test

Primary outcomes:
measure: Relevant indexes after treatment
timeFrame: The day of admission, day one, day two, day three, day five, day seven, day ten
Secondary outcomes:
Other outcomes:
Locations:
city: Changchun
country: China
facility: The First Hospital of Jilin University
state: Ji Lin
Study officials:
affiliation: The First Hospital of Jilin University
name: Dan Li, Doctor
role: STUDY_DIRECTOR
References:
Clinical trial NCT00715286: Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study
Official title: Neoadjuvant Chemotherapy (NACT) Followed by Interval Debulking Surgery vs Upfront Surgery Followed by Chemotherapy (CT) in Advanced Epithelial Ovarian Carcinoma (EOC): A Prospective Randomized Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Ovarian Carcinoma
Keywords: epithelial ovarian cancer
neoadjuvant chemotherapy
randomized study
Lead sponsor: All India Institute of Medical Sciences
Sponsor class: OTHER
First posted: 2008-07-15
Enrollment: 180
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To determine the impact of Neoadjuvant chemotherapy on surgical debulking rate, overall and disease-free survival and quality of life (QOL) in patients with advanced EOC.


Eligibility criteria: Inclusion Criteria:

* Age:20 to 65 years
* Epithelial ovarian carcinoma
* Stage IIIc \& IV (pleural effusion only)
* ECOG PS 0-2
* Cytology/biopsy positive patients
* Good compliance
* Previously untreated patients

Exclusion Criteria:

* Any medical contraindication of surgery
* Psychiatric illness
* Cardiac, liver or renal dysfunction

Primary outcomes:
measure: to compare the optimal debulking rate in primary surgery group and neoadjuvant chemotherapy group
timeFrame: post surgery
Secondary outcomes:
measure: post operative morbidity
timeFrame: 3 weeks post op
Other outcomes:
Locations:
city: New Delhi
country: India
facility: All India Institute of Medical Sciences
state: Delhi
Study officials:
affiliation: All India Institute of Medical Sciences
name: Lalit Kumar, DM
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04767386: Relation Between Near Point of Convergence and Postural Stability in Subjects with Non Specific Cervical Pain
Official title: Relation Between Near Point of Convergence and Postural Stability in Subjects with Non Specific Cervical Pain
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neck Pain
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2021-02-23
Enrollment: 80
Sex: ALL
Minimum age (years): 30
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Egyptian subjects

Brief summary: A correlation study was conducted to correlate between the convergence insufficiency and postural stability at three different cervical positions in patients with non-specific cervical pain.

Detailed description: A correlational study was conducted on eighty (male and female) subjects aged between 30-40 years old, presented with chronic NSCP persisted for six months or more, with neck disability index score (NDI) ≥10%, and can possess at least 45° of left and right cervical rotation participated in the study. Convergence insufficiency was evaluated by the near point of conversion (NPOC) rule and postural instability was examined by the Biodex balance system. RESULTS: There was significant positive correlation between (NPOC) and anteroposterior stability index (APSI) at the three cervical positions; neutral, 45° right torsion and 45° left torsion (P\>0.05).

Eligibility criteria: Inclusion Criteria:

* Age from 30 to 40 years.
* Chronic cervical pain ( 6 to18 months ago).
* Neck Disability Index (NDI) score ≥10%),
* Move 45° of cervical rotation to both the left and right.

Exclusion Criteria:

-Neuromuscular or musculoskeletal disorders.

Primary outcomes:
measure: Stability index
timeFrame: during the procedure
measure: The near point of convergence (NPOC)
timeFrame: during the procedure
measure: The CROM
timeFrame: during the procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Faculty of Physical Therapy Cairo University
state: Cairo
Study officials:
affiliation: Cairo University
name: Wael Shendy, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT06201286: Effect of Manual Therapy on Obese Individuals With Low Back Pain
Official title: Pain, Function and Range of Motion Related Outcomes of Mulligan Concept Applications in Obese Individuals With Chronic Mechanical Low Back Pain: a Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Low Back Pain, Mechanical
Obesity
Keywords: Mulligan concept
Range of Motion
Low Back Pain
Obesity
Lead sponsor: Abant Izzet Baysal University
Sponsor class: OTHER
First posted: 2024-01-11
Enrollment: 46
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This study will investigate the effectiveness of Mulligan mobilisation techniques Sustained Natural Apophyseal Glides (SNAGS) and Natural Apophyseal Glides (NAGs) on pain, disability, and range of motion (ROM) in obese individuals with mechanical low back pain (LBP).

Detailed description: One of the most important methods in the treatment of LBP in recent years is manual therapy; manipulation, mobilisation and soft tissue techniques. With the manual techniques applied to the spine, the position and placement of the anatomical structures are changed and the tight and tense tissues are loosened. It has been observed that Mulligan techniques can correct the faults that cause pain in the spine and that the structures that cause pain return to their normal functions when released. In the literature, it has recently been observed that the number of studies examining manual therapy and Mulligan Concept methods has increased. Studies examining the effect of SNAG method on the lumbar region (12) and the effect of mobilisation and taping on chronic low back pain were found. However, no study was found in which SNAG and NAGS applications were applied on obese patients diagnosed with mechanical low back pain. Therefore, in this study, SNAG and NAGS in obese patients with LBP to investigate the effectiveness of the practices

Eligibility criteria: Inclusion Criteria:

diagnosed with mechanical low back pain, Body Mass Index (BMI) was between 30.00-39.99, 1.-2. Forty-six patients, aged 20-50 years, who were extremely obese and had pain radiating to the lower back and hips for at least 3 months,

Exclusion Criteria:

-

Primary outcomes:
measure: Pain Assessment
timeFrame: Two times in 11 day (before intervention, immediately after last intervention)
measure: The Oswestry Low Back Pain Disability Questionnaire
timeFrame: Two times in 11 day (before intervention, immediately after last intervention)
measure: Joint Range of Motion Assessment (ROM)
timeFrame: Two times in 11 day (before intervention, immediately after last intervention)
Secondary outcomes:
Other outcomes:
Locations:
city: Bolu
country: Turkey
facility: Faculty of Health Sciences Bolu Abant İzzet Baysal University
Study officials:
affiliation: Bolu Abant İzzet Baysal University
name: Ömer Osman PALA, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06903286: Extension Study of Participants From SPG302-ALS-001
Official title: An Open-label Extension of SPG302-ALS-001 Study to Evaluate the Long-term Safety and Efficacy of Daily Oral SPG302 Treatment in Participants With Amyotrophic Lateral Sclerosis
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Amyotrophic Lateral Sclerosis (ALS)
Keywords: Amyotrophic Lateral Sclerosis
regenerative
synapse
Lead sponsor: Spinogenix
Sponsor class: INDUSTRY
First posted: 2025-03-30
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Open Label extension
Primary purpose: TREATMENT

Brief summary: This study will evaluate the long-term safety and efficacy of participants enrolled in SPG302-ALS-101 with Amyotrophic Lateral Sclerosis (ALS)

Detailed description: This is an open-label extension study of SPG302-ALS-001 to investigate the long-term safety, tolerability, and efficacy of SPG302 administered orally in participants with Amyotrophic Lateral Sclerosis (ALS). This study will allow participants in the parent study to continue dosing. Enrolled participants will continue at the dose they received at the end of the first trial, and will self-administer SPG302 orally every day for up to 52 weeks. Participants will have an in-person clinic visit every 3 months (± 3 days) and a monthly phone visit. An end of treatment visit will occur within 7 days of the last dose of SPG302. A final visit to collect safety data will be conducted up to 1 month (± 3 days) post last dose.

Eligibility criteria: Inclusion Criteria:

• Must have participated in all study activities of SPG302-ALS-001, the parent study

Exclusion Criteria:

* Unable to reliably and regularly swallow whole oral medications on a daily basis.
* Medical conditions that investigator or sponsor determine would interfere with participation in clinical trial

Primary outcomes:
measure: Treatment emergent adverse events and serious adverse events
timeFrame: Up to 52 weeks
measure: C-SSRS (Columbia Suicide Severity Rating Scale)
timeFrame: Up to 52 weeks
Secondary outcomes:
measure: Change in the Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRS-R) scores
timeFrame: up to 52 weeks
measure: Change in Edinburgh Cognitive and Behavioural ALS Screen (ECAS)
timeFrame: up to 52 weeks
measure: Changes from baseline in neurofilament light biomarker (NfL)
timeFrame: up to 52 weeks.
Other outcomes:
Locations:
city: North Ryde
country: Australia
facility: Macquarie University
state: New South Wales
city: Herston
country: Australia
facility: Royal Brisbane and Women's Hospital
state: Queensland
city: Adelaide
country: Australia
facility: Flinders Medical Center
state: South Australia
Study officials:
References:
Clinical trial NCT01556386: Pharmacogenetic Analysis of Korean Pediatric Patients With Acute Lymphoblastic Leukemia
Official title: Pharmacogenetic Analysis of Korean Pediatric Patients With Acute Lymphoblastic Leukemia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Lymphoblastic Leukemia
Keywords: acute lymphoblastic leukemia
single nucleotide polymorphism
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2012-03-16
Enrollment: 200
Sex: ALL
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All the patients with acute lymphoblastic leukemia who was diagnosed and treated in SNUCH.

Brief summary: This study is to find out distribution of genetic polymorphisms and genes related to the chemotherapeutic drugs of ALL.

Detailed description: Cure rate of pediatric ALL dramatically improved over 80%. Resistance to drug and hematologic relapse are remaining problem in ALL treatment. One of the explanations of drug resistance and toxicities is the pharmacogenetic effect. Germline polymorphisms in genes that code for proteins involved in the pharmacokinetics and pharmacodynamics of antileukemic agents are various, and inter-patient variability is the main factor for pharmacogenetic difference. Since multiple chemotherapeutic agents are involved in treating ALL, many genes related to the metabolic pathways of those drugs have an effect on the pharmacokinetics of patients with ALL. In Korea, pharmacogenetic study including multiple genetic loci for pediatric ALL has not been reported.In this study, the distribution of genetic polymorphisms and genes related to antileukemic drugs were analyzed, and their relations to the outcome of treatment and relapse rates were assessed.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of acute lymphoblastic leukemia
* In case of informed consent and assent

Exclusion Criteria:

* Paients or parents refusal

Primary outcomes:
measure: To find out distribution of genetic polymorphisms genes related to the pharmacodynamics of the ALL therapy
timeFrame: up to 3 years from diagnosis
Secondary outcomes:
measure: To see the ethnic difference of genetic polymorphisms related to the chemotehrapeutic drugs of ALL
timeFrame: whenever after diagnosis and genetic analysis (no time frame needed)
measure: To find out relation of genetic polymorphisms and clinical outcome (relapse or survival)
timeFrame: up to 3 years from diagnosis
measure: To find out risk factors of relapse and death
timeFrame: up to 3 years from diagnosis
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
state: Chongno-gu
Study officials:
affiliation: Seoul National University Hospital
name: Hyoung Jin Kang, MD. PhD.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02691286: Circulating microRNAs in Patients With STEMI Complicated With Cardiogenic Shock
Official title: Prognostic Value of Circulating microRNAs in Patients With ST-elevation Myocardial Infarction (STEMI) Complicated by Cardiogenic Shock
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: STEMI
Cardiogenic Shock
Acute Coronary Syndrome
microRNA
Lead sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Sponsor class: OTHER
Collaborators: name: Spanish Society of Cardiology
First posted: 2016-02-25
Enrollment: 142
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients admitted to Hospital de la Santa Creu i Sant Pau with diagnosis of STEMI with or without cardiogenic shock

Brief summary: The aim of the study is knowing the prognostic value of circulating miRNAs in patients admitted to our hospital with STEMI complicated with cardiogenic shock.


Eligibility criteria: Inclusion Criteria:

* Age \> 18 years
* ST elevation by ECG diagnostic of STEMI
* Evidency of coronary occlusion in coronariography
* Signed informed consent

Exclusion Criteria:

* Patients admitted from other hospitals
* Impossibility of getting blood samples in first 6h
* Declined consent

Primary outcomes:
measure: Mortality
timeFrame: up to 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital de la Santa Creu i Sant Pau
Study officials:
affiliation: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
name: Jordi Sans-Roselló, M.D.
role: PRINCIPAL_INVESTIGATOR
References: